CAPR Company Profile and Key Details

Q: Who are the executives of CAPR?

Dr. Deborah D. Ascheim M.D.ConsultantCatherine Lee KelleherConsultantDr. Deborah D. AscheimConsultantMr. Xavier AvatChief Bus. OfficerDr. Frank Isaac Litvack FACC, M.D.Executive ChairmanDr. Linda Marbán Ph.D.Co-Founder, Pres, Chief Executive Officer & DirectorMr. Anthony J. Bergmann M.B.A.Chief Financial Officer & Corporation TreasurerMs. Karen G. KrasneyExecutive Vice President, Gen. Counsel & Sec.Dr. Eduardo MarbánCo-Founder & Chairman of Scientific Advisory BoardDr. Kristi A. H. Elliott Ph.D.Chief Science Officer

NASDAQ : CAPR

Capricor Therapeutics

$35.99

5.36+17.50%

Open: 10:43 AM

70.34

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Capricor Therapeutics, Inc. (CAPR) stock surged +17.50%, trading at $35.99 on NASDAQ, up from the previous close of $30.63. The stock opened at $32.50, fluctuating between $32.08 and $36.44 in the recent session.

Stock Snapshot

30.63

Prev. Close

1.65B

Market Cap

32.08

Day Low

-20.57

P/E Ratio

-1.75

EPS (TTM)

-0.9

Cash Flow per Share

32.5

Open

45.72M

Number of Shares

36.4383

Day High

87.9%

Free Float in %

0.74

Book Value

2.33M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Mar 09, 2026	30.77	31.41	28.98	30.63	2.66M
Mar 06, 2026	25.41	28.89	25.08	27.90	2.05M
Mar 03, 2026	25.62	26.52	25.12	25.84	761.66K
Mar 02, 2026	26.69	27.63	26.30	26.86	669.33K
Feb 27, 2026	27.76	27.98	27.13	27.93	1.37M
Feb 26, 2026	28.40	28.45	27.45	27.89	666.52K
Feb 25, 2026	27.99	28.88	27.88	28.35	523.6K
Feb 24, 2026	27.65	28.03	27.07	27.91	779.31K
Feb 23, 2026	28.16	29.08	27.32	27.87	746.25K
Feb 20, 2026	28.70	29.40	27.54	28.51	2.05M
Feb 19, 2026	25.47	29.28	25.07	29.15	2.36M
Feb 18, 2026	22.99	26.15	22.80	25.53	2.02M
Feb 17, 2026	22.49	23.34	22.05	23.03	872.33K
Feb 13, 2026	24.24	24.36	22.26	22.45	914.65K
Feb 12, 2026	24.00	24.48	23.23	23.67	779.55K
Feb 11, 2026	24.77	25.08	23.81	24.20	603.22K
Feb 10, 2026	25.20	25.45	24.50	24.63	750.42K
Feb 09, 2026	24.72	25.33	24.26	25.19	656.37K
Feb 06, 2026	23.36	25.21	23.23	24.72	1.07M
Feb 05, 2026	24.14	24.83	22.70	23.03	1.2M

Contact Details

San Diego, CA 92121

United States

https://www.capricor.com 310 358 3200

About Company

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.

Stock Peers

REGN

21.74+2.86%

Regeneron Pharmaceuticals, Inc.$781.60 ARGX

22.6+3.15%

argenx SE$740.40 UTHR

51.01+10.67%

United Therapeutics Corporation$529.17 VRTX

4.18+0.92%

Vertex Pharmaceuticals Incorporated$460.87 MDGL

0.37+0.09%

Madrigal Pharmaceuticals, Inc.$433.20 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ALNY

2.93+0.91%

Alnylam Pharmaceuticals, Inc.$323.59 PRAX

-1.7-0.55%

Praxis Precision Medicines, Inc.$309.01 KRYS

4.96+1.96%

Krystal Biotech, Inc.$258.65 ASND

-0.73-0.30%

Ascendis Pharma A/S$239.92

Company Overview

Capricor Therapeutics, Inc. (NASDAQ:CAPR) closed at $35.99 USD, gaining $5.36 (17.50%) from the previous close of $30.63. The stock is currently mid-range between its 52-week high and low $4.30 and $40.37. With a market capitalization of about $1.65 billion, Capricor Therapeutics, Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~0.48). Key stats such as the average daily volume over the past year has been around 1.24 million shares, trading with heavier-than-usual volume. Headquartered in San Diego, CA, Capricor Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Linda Marbán, the company employs approximately 160 people and listed since February 13, 2007. Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders.

Technical Performance

Short-term trend indicators are mixed aligned (SMA20 10.87%, SMA50 8.65%, SMA200 113.05%). The stock’s 14-day RSI is 59.98 (neutral), while the ATR of 1.68 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -30.91% below its high and over 548.6% above its low. Average 10-day trading volume of 1.54 million shares is slightly above the 3-month average of 1.25 million, indicating heightened recent market interest.

Valuation Metrics

Capricor Therapeutics, Inc. trades at a P/E ratio of -16.82, slightly below the S&P 500 average, with a price-to-sales ratio of 123.9 and a price-to-book ratio of 16.44 reflecting a rich premium to book value. The P/FCF stands at -20.17, also above market averages. Compared to sector medians, Capricor Therapeutics, Inc. P/S is trading rich, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Dividend & Fair Value

Capricor Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$11.26. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Capricor Therapeutics, Inc. generated EPS of -$1.80 over the past year. Five-year average earnings growth is 11.01%. The latest quarter delivered EPS of -$0.54. The next quarter is forecast at -$0.51. Next year's EPS is expected at -$2.81. Analyst sentiment is bullish. Analyst rating data shows there are 4 Strong Buy ratings, 15 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $77.00 to $12.00. The high target offers 151.39% upside. The low target suggests -60.82% downside. The mean target is $41.95. This offers 36.96% upside. Capricor Therapeutics, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended November 10, 2025, missed forecasts by 0.0%. The prior quarter beat by 18.75%. Over the last six quarters, Apple has recorded several small beats. These include 9.37% in August 07, 2024.

Shareholding & Insider Activity

Capricor Therapeutics, Inc. has 45.72 million shares outstanding. The public float is 40.19 million shares, elevated short interest at 28.25% of float. This equals 11.35 million shares. The short ratio is 5.87 days. Institutional investors hold 36.69% of the float. Insiders own 16.79%. Nippon Shinyaku Co Ltd holds 7.09 million shares, CEDARS SINAI MEDICAL CENTER has 4.05 million shares and TANEN DAVID M has 1.52 million shares.

Financial & Profitability Overview

Over the trailing twelve months, Capricor Therapeutics generated $25.18M in revenue, or $0.94 per share. Gross margin was 95.75%, operating margin -95.63%, and net profit margin -88.52%. Returns are negative, with ROA at -37.95% and ROE at -98.61%.
On valuation metrics, Capricor Therapeutics trades at a P/E of -16.82, P/S of 123.90 and P/B of 16.44. The current ratio is 3.59 and quick ratio is 3.59. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -11.14 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.17, supported by a cash flow-to-debt ratio of -4.20.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Capricor Therapeutics posted revenue of $25.18M, down slightly from $2.55M in the prior quarter. Gross profit was $24.11M (margin 95.75%). Operating income was - $24.08M (margin -95.6%). Net income was- $22.29M (EPS - $0.83).
The company ended the quarter with $39.49M in cash and short-term investments, a total debt of $5.61M, and net debt of - $9.08M. Total assets were $58.73M, with equity of $22.60M. Financials further reflected weakness, with operating cash flow of - $25.60M, free cash flow of - $27.64M, and capital expenditures of - $2.05M.

Price Forecast & Outlook

Our AI price prediction model suggests that Capricor Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 2.55%, with price expected at $31.41 by March 23, 2026, within a range of $29.78 to $33.19 3-Month Outlook: Projected rise of 55.31%, reaching $47.57 by June 05, 2026, with a range of $46.83 to $48.39. 1-Year Outlook: Projected gain of 16.81%, with price at $35.78 by March 09, 2027, within a range of $33.70 to $37.57.

Key Takeaways

Capricor Therapeutics, Inc. (NASDAQ:CAPR) shares are down -16.15% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Capricor Therapeutics, Inc. trading at a premium to the broader market with a P/E of -16.82. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $34.78, suggesting 13.55% upside. Our AI forecast model points to short-term strength (2.55% over two weeks), a medium-term rise (55.31% over three months), and a longer-term gain (16.81% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Capricor Therapeutics, Inc. (CAPR) stock price?

Capricor Therapeutics, Inc. (NASDAQ: CAPR) stock price is $35.99 in the last trading session. During the trading session, CAPR stock reached the peak price of $36.44 while $32.08 was the lowest point it dropped to. The percentage change in CAPR stock occurred in the recent session was 17.5% while the dollar amount for the price change in CAPR stock was $5.36.

CAPR's industry and sector of operation?

The NASDAQ listed CAPR is part of Biotechnology industry that operates in the broader Healthcare sector. Capricor Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of CAPR?

Dr. Deborah D. Ascheim M.D.
Consultant
Catherine Lee Kelleher
Consultant
Dr. Deborah D. Ascheim
Consultant
Mr. Xavier Avat
Chief Bus. Officer
Dr. Frank Isaac Litvack FACC, M.D.
Executive Chairman
Dr. Linda Marbán Ph.D.
Co-Founder, Pres, Chief Executive Officer & Director
Mr. Anthony J. Bergmann M.B.A.
Chief Financial Officer & Corporation Treasurer
Ms. Karen G. Krasney
Executive Vice President, Gen. Counsel & Sec.
Dr. Eduardo Marbán
Co-Founder & Chairman of Scientific Advisory Board
Dr. Kristi A. H. Elliott Ph.D.
Chief Science Officer

How CAPR did perform over past 52-week?

CAPR's closing price is 612.33% higher than its 52-week low of $4.30 where as its distance from 52-week high of $40.37 is -24.13%.

How many employees does CAPR have?

Number of CAPR employees currently stands at 160.

Link for CAPR official website?

Official Website of CAPR is: https://www.capricor.com

How do I contact CAPR?

CAPR could be contacted at phone 310 358 3200 and can also be accessed through its website. CAPR operates from 10865 Road to the Cure, San Diego, CA 92121, United States.

How many shares of CAPR are traded daily?

CAPR stock volume for the day was 2.33M shares. The average number of CAPR shares traded daily for last 3 months was 1.24M.

What is the market cap of CAPR currently?

The market value of CAPR currently stands at $1.65B with its latest stock price at $35.99 and 45.72M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	160
Beta	0.48
Sales or Revenue	$25.18M
5Y Sales Change%	0.653%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

CAPR Company Profile and Key Details

Capricor Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Company Overview

Shareholding & Insider Activity

Dividend & Fair Value

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Valuation Metrics

Key Takeaways